342 related articles for article (PubMed ID: 24097870)
21. High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancer.
Gately K; Forde L; Cuffe S; Cummins R; Kay EW; Feuerhake F; O'Byrne KJ
Clin Lung Cancer; 2014 Jan; 15(1):58-66. PubMed ID: 24210543
[TBL] [Abstract][Full Text] [Related]
22. High expression of trimethylated histone H3 at lysine 27 predicts better prognosis in non-small cell lung cancer.
Chen X; Song N; Matsumoto K; Nanashima A; Nagayasu T; Hayashi T; Ying M; Endo D; Wu Z; Koji T
Int J Oncol; 2013 Nov; 43(5):1467-80. PubMed ID: 23969945
[TBL] [Abstract][Full Text] [Related]
23. Distinct prognostic values and potential drug targets of ALDH1 isoenzymes in non-small-cell lung cancer.
You Q; Guo H; Xu D
Drug Des Devel Ther; 2015; 9():5087-97. PubMed ID: 26366059
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.
Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ
J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667
[TBL] [Abstract][Full Text] [Related]
25. Extracapsular extension is a powerful prognostic factor in stage IIA-IIIA non-small cell lung cancer patients with completely resection.
Liu W; Shao Y; Guan B; Hao J; Cheng X; Ji K; Wang K
Int J Clin Exp Pathol; 2015; 8(9):11268-77. PubMed ID: 26617851
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of CD151 overexpression in non-small cell lung cancer.
Kwon MJ; Seo J; Kim YJ; Kwon MJ; Choi JY; Kim TE; Lee DH; Park S; Shin YK; Han J; Choi YL
Lung Cancer; 2013 Jul; 81(1):109-16. PubMed ID: 23570797
[TBL] [Abstract][Full Text] [Related]
27. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas.
Kidani K; Osaki M; Tamura T; Yamaga K; Shomori K; Ryoke K; Ito H
Oral Oncol; 2009 Jan; 45(1):39-46. PubMed ID: 18619895
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of MCM7 expression in the bronchial brushings of patients with non-small cell lung cancer (NSCLC).
Liu YZ; Jiang YY; Hao JJ; Lu SS; Zhang TT; Shang L; Cao J; Song X; Wang BS; Cai Y; Zhan QM; Wang MR
Lung Cancer; 2012 Jul; 77(1):176-82. PubMed ID: 22456526
[TBL] [Abstract][Full Text] [Related]
29. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus.
Yamada A; Fujii S; Daiko H; Nishimura M; Chiba T; Ochiai A
Int J Oncol; 2011 Feb; 38(2):345-53. PubMed ID: 21165554
[TBL] [Abstract][Full Text] [Related]
30. The association and prognostic impact of enhancer of zeste homologue 2 expression and epithelial-mesenchymal transition in resected lung adenocarcinoma.
Matsubara T; Toyokawa G; Takada K; Kinoshita F; Kozuma Y; Akamine T; Shimokawa M; Haro A; Osoegawa A; Tagawa T; Mori M
PLoS One; 2019; 14(5):e0215103. PubMed ID: 31042721
[TBL] [Abstract][Full Text] [Related]
31. Peroxiredoxin 4 as an independent prognostic marker for survival in patients with early-stage lung squamous cell carcinoma.
Hwang JA; Song JS; Yu DY; Kim HR; Park HJ; Park YS; Kim WS; Choi CM
Int J Clin Exp Pathol; 2015; 8(6):6627-35. PubMed ID: 26261544
[TBL] [Abstract][Full Text] [Related]
32. Quantitative analysis of EZH2 expression and its correlations with lung cancer patients' clinical pathological characteristics.
Wan L; Li X; Shen H; Bai X
Clin Transl Oncol; 2013 Feb; 15(2):132-8. PubMed ID: 22855181
[TBL] [Abstract][Full Text] [Related]
33. Increased EZH2 expression is associated with proliferation and progression of cervical cancer and indicates a poor prognosis.
Liu Y; Liu T; Bao X; He M; Li L; Yang X
Int J Gynecol Pathol; 2014 May; 33(3):218-24. PubMed ID: 24681730
[TBL] [Abstract][Full Text] [Related]
34. Co-expression of Bmi1 and EZH2 as an independent poor prognostic factor in esophageal squamous cell carcinoma.
Ha SY; Kim SH
Pathol Res Pract; 2012 Aug; 208(8):462-9. PubMed ID: 22766604
[TBL] [Abstract][Full Text] [Related]
35. EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study.
Li AM; Dunham C; Tabori U; Carret AS; McNeely PD; Johnston D; Lafay-Cousin L; Wilson B; Eisenstat DD; Jabado N; Zelcer S; Silva M; Scheinemann K; Fryer C; Hendson G; Fotovati A; Hawkins C; Yip S; Dunn SE; Hukin J
Cancer; 2015 May; 121(9):1499-507. PubMed ID: 25586788
[TBL] [Abstract][Full Text] [Related]
36. Increased expression of SOX4 is a biomarker for malignant status and poor prognosis in patients with non-small cell lung cancer.
Wang D; Hao T; Pan Y; Qian X; Zhou D
Mol Cell Biochem; 2015 Apr; 402(1-2):75-82. PubMed ID: 25567207
[TBL] [Abstract][Full Text] [Related]
37. Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer.
Sepesi B; Cuentas EP; Canales JR; Behrens C; Correa AM; Vaporciyan A; Weissferdt A; Kalhor N; Moran C; Swisher S; Wistuba I
Semin Thorac Cardiovasc Surg; 2017 Autumn; 29(3):408-415. PubMed ID: 29195578
[TBL] [Abstract][Full Text] [Related]
38. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.
Shiogama S; Yoshiba S; Soga D; Motohashi H; Shintani S
Anticancer Res; 2013 Oct; 33(10):4309-17. PubMed ID: 24122997
[TBL] [Abstract][Full Text] [Related]
39. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.
Moldvay J; Scheid P; Wild P; Nabil K; Siat J; Borrelly J; Marie B; Farré G; Labib T; Pottier G; Sesboüé R; Bronner C; Vignaud JM; Martinet Y; Martinet N
Clin Cancer Res; 2000 Mar; 6(3):1125-34. PubMed ID: 10741743
[TBL] [Abstract][Full Text] [Related]
40. Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis.
Tang X; Kadara H; Behrens C; Liu DD; Xiao Y; Rice D; Gazdar AF; Fujimoto J; Moran C; Varella-Garcia M; Lee JJ; Hong WK; Wistuba II
Clin Cancer Res; 2011 Apr; 17(8):2434-43. PubMed ID: 21257719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
